11.98
+0.01(+0.08%)
Currency In USD
| Previous Close | 11.97 |
| Open | 11.99 |
| Day High | 12.32 |
| Day Low | 11.9 |
| 52-Week High | 12.49 |
| 52-Week Low | 5.41 |
| Volume | 1.38M |
| Average Volume | 1.92M |
| Market Cap | 1.04B |
| PE | -4.83 |
| EPS | -2.48 |
| Moving Average 50 Days | 10.23 |
| Moving Average 200 Days | 7.61 |
| Change | 0.01 |
If you invested $1000 in Kura Oncology, Inc. (KURA) 10 years ago, it would be worth $1,541.83 as of December 04, 2025 at a share price of $11.98. Whereas If you bought $1000 worth of Kura Oncology, Inc. (KURA) shares 5 years ago, it would be worth $325.54 as of December 04, 2025 at a share price of $11.98.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
GlobeNewswire Inc.
Yesterday at 1:32 PM GMT
Event Scheduled for December 8, 2025 at 12:30 PM ETSAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, t
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
GlobeNewswire Inc.
Dec 02, 2025 1:02 PM GMT
SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the first U.S. commercial sa
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
GlobeNewswire Inc.
Nov 25, 2025 10:16 PM GMT
KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated AML, is now commercially available in the United StatesSAN DIEGO and TOKYO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and K